Abstract
We investigated the role of the KIR loci and their HLA class I ligands in a large cohort of African American multiple sclerosis (MS) patients (N=907) and controls (N=1456). No significant differences in carrier frequencies for any KIR locus or haplotype were observed between cases and controls. However, examination of KIR in the context of their cognate HLA ligands revealed a strong protective effect for KIR3DL1 in combination with HLA-A and -B alleles bearing the Bw4 motif (P=10−8; odds ratio (OR)=0.60, confidence interval (CI)=0.50–0.71) and the Bw4 ligand alone (P<10−6; OR=0.63, CI=0.53–0.75). The observed effect cannot be explained by either a specific HLA-B allele or by linkage disequilibrium with HLA-DRB1 or HLA-A. The protective effect was observed only in individuals who were not positive for the MS risk allele HLA-DRB1*15:01 (P<10−6; OR=0.61, CI=0.51–0.74). Our study, the first investigation of KIR and MS in African Americans, confirms and refines previous findings in a European cohort.
Similar content being viewed by others
Introduction
The important role of variation in genes of the human leukocyte antigen (HLA) complex in genetic predisposition to multiple sclerosis (MS) has long been recognized. However, in addition to their role in antigen presentation to T cells, HLA class I molecules also serve as ligands for killer immunoglobulin-like (KIR) molecules. An ever-increasing pace of investigation over the last decade has demonstrated definitively that KIR receptors play critical roles in transplantation success and disease pathogenesis.1, 2, 3, 4
Expressed on the surface of natural killer (NK) cells, KIR serve to mediate cytolytic killing and cytokine secretion.5 The KIR gene complex on human chromosome 19q13.4 encodes both inhibitory and activating receptors, with significant variation in gene content between individuals and populations. Any given KIR haplotype may contain from 4 to 14 genes, and are generally categorized into two groups, termed A and B.6 KIR molecules recognize specific epitopes on HLA class I: KIR3DL2 and KIR2DS4 recognize HLA-A molecules with the A3/A11 epitope, while KIR2DL1, KIR2DL2/3, KIR2DS1, KIR2DS2 and KIR2DS4 interact with either the C1 or C2 epitopes on HLA-C; a small subset of HLA-B molecules also carry the C1 epitope, and are capable of interacting with these KIR. Finally, KIR3DL1 binds HLA-A and -B molecules that carry the Bw4 specificity.2, 7, 8, 9
Only a handful of studies have been conducted examining KIR variation in MS, but overall, the analysis of KIR gene-content variation has pointed to a role for the KIR in disease susceptibility. In patients of European ancestry, predisposition to MS has been variably associated with the absence of the inhibitory KIR2DL3 (ref.10) or the presence of activating KIR2DL5 and KIR3DS1. In other studies, KIR2DS1 was found to be protective in MS.11, 12 In the largest previous study to-date, the HLA class I Bw4 motif was found to be protective in a Norwegian cohort, but no association was observed between KIR carrier frequencies and MS.13
All prior examination of the role of KIR in MS has been conducted in cohorts of European origin. While conventional wisdom has held that MS is much less common in African Americans relative to European Americans, more recent data suggests that risk for MS in African Americans is higher than expected and its incidence in this group is increasing.14, 15 Importantly, African Americans are more likely to have a more acute disease course and it appears that this increased severity is partially associated with African ancestry.16, 17 Examination of HLA associations with MS in African Americans has served to clarify HLA class II haplotypic associations18 and revealed a role for HLA-DRB5.19 Here, we investigate the role of the KIR loci and their HLA class I ligands in a large cohort of African American MS patients and controls. In addition to being the first investigation of KIR and autoimmune disease in African Americans, this study represents the largest case-control analysis conducted to-date in any population examining KIR and HLA variation in MS.
Results and discussion
No significant difference in carrier frequencies for any KIR locus (or allele in the case of KIR2DL2/3 and KIR3DL1/S1), were observed between cases and controls (Table 1). We also examined whether specific haplotypic structures of the KIR were associated, rather than individual loci, both across the entire KIR cluster and within each of the centromeric and telomeric regions. No significant associations were observed for any specific KIR gene-content haplotype or particular combinations of KIR A and B haplotypes (data not shown).
However, examination of KIR in the context of their cognate HLA ligands (Table 2) revealed a strong protective effect for KIR3DL1 in combination with HLA-A and -B alleles bearing the Bw4 motif (P=10−8; odds ratio (OR)=0.60, confidence interval (CI)=0.50–0.71). Because nearly every individual in this cohort is positive for KIR3DL1 (Table 1), a protective effect is also expected and observed for the Bw4 ligand alone (Table 3; P<10−6; OR=0.63, CI=0.53–0.75). These results are in keeping with those observed in the Norwegian cohort,13 where, as in most populations20 the carrier frequency of KIR3DL1 is also very high. No other HLA ligand was independently associated with disease.
We tested all HLA-B alleles for association with disease in order to determine whether the Bw4-mediated effect could be attributed to one or a few specific HLA-B alleles. Only one HLA-B allele, HLA-B*53 would be considered significantly protective in this cohort after Bonferroni correction for multiple tests (<0.002). While this allele does have the Bw4 motif, it is not present at sufficient frequency in this cohort (<4% in cases and controls; Supplementary Table 1) to account for the observed Bw4 association. We therefore considered whether the observed association with Bw4 could be attributed to linkage disequilibrium of Bw4-bearing HLA-B alleles with specific MS-associated HLA alleles at other loci.
When two locus haplotypes (HLA-B~HLA-DRB1 and HLA-A~HLA-B) are considered with HLA-B alleles coded for either the Bw4 or Bw6 motif, in each case the most significantly protective haplotype bears a Bw4 HLA-B allele, while the HLA-A and HLA-DRB1 alleles vary (Table 4). For example, when HLA-DRB1 is considered alone, protection is conferred by the common allele HLA-DRB1*11 (P=0.0001; OR=0.69, CI=0.57–0.84). Likewise, the most highly significant protective HLA-DRB1~HLA-Bw4/6 haplotype is HLA-DRB1*11~Bw4 (P<10−6; OR=0.50, CI=0.34–0.72). In contrast, the HLA-DRB1*11~Bw6 haplotype is not significantly associated with disease. Similarly, the two other haplotypes observed to be protective in this cohort are HLA-DRB1*13~Bw4 (P<0.05; OR=0.67, CI=0.49–0.93) and HLA-DRB1*07~Bw4 (P<0.05; OR=0.58, CI=0.40–0.85), but their Bw6-bearing counterparts are not. In each of these cases, the Bw4 and Bw6 bearing HLA-DRB1 haplotypes are present at roughly equal frequencies, thus ruling out linkage disequilibrium as a source of the disparate effects.
When we consider common (frequency >0.03%) haplotypes with HLA-A, only HLA-A*02~Bw4 is significantly protective in this cohort (P=0.003; OR=0.70, CI=0.55–0.88). When HLA-A is considered alone (Supplementary Table 1), HLA-A*02 is not protective, nor is it protective in the context of Bw6 rather than Bw4 bearing HLA-B alleles (Table 4). Taken together, the haplotype data indicate that the protective effect is being mediated by the presence of the Bw4 epitope that confers KIR3DL1 ligand status to HLA-B alleles. The observed effect cannot be explained by either a specific HLA-B allele defined with respect to the antigen-binding domain (at single-field resolution) or by any protective HLA-DRB1 or HLA-A alleles in linkage disequilibrium with Bw-bearing HLA-B alleles, supporting the relevance of the KIR-HLA framework in disease risk.
The strong predisposing effect of HLA-DRB1*15:01 in MS has long been recognized, and in this cohort HLA-DRB1*15:01, like nearly most others examined to-date,21 is the primary predisposing HLA variant with OR>2 (Supplementary Table 1). Given the strong and significant role for HLA-DRB1*15:01, we explored whether protection mediated via KIR3DL1/HLA-Bw4 is differentially associated with regard to HLA-DRB1*15:01 status. Cases and controls were stratified according to having 0, 1 or 2 copies of HLA-DRB1*15:01, and association of KIR3DL1/Bw4 with disease was examined within each stratum (Table 5). The protective effect was observed only in individuals who were not positive for HLA-DRB1*15:01 (P<10−6; OR=0.61, CI=0.51–0.74). These data suggest that while the KIR-ligand combination mediates a robust protective effect, that effect is overridden in the presence of the strong predisposing effect of HLA-DRB1*15:01. Analysis of HLA-B~HLA-DRB1 haplotypes in HLA-DRB1*15:01-negative individuals yields results similar to those described above for the entire cohort (data not shown), implying that differential association of KIR3DL1/Bw4 is not mediated by linkage disequilibrium between HLA-DRB1 and HLA-B alleles.
Given the extensive allelic polymorphism of KIR3DL1, future studies examining KIR in MS will benefit from high-resolution genotyping, particularly in populations with African ancestry. For example, a non-expressed variant, KIR3DL1*004 (ref. 22) is observed at relatively high frequencies in a West African population.23 It is also interesting to note that KIR3DL1 and HLA-Bw4 were found to be subject to co-evolution in this same population, suggesting a selective advantage for this KIR-HLA combination.
In conclusion, our data in a large African American cohort confirm and refine a previous finding in a large Norwegian cohort13 of protection from MS mediated by the KIR3DL1 ligand HLA-Bw4, either alone or in combination with KIR3DL1. The fact that our results in a large African American cohort also implicate Bw4, despite the fact that individuals with European and African ancestry have vastly different HLA-B allelic variation and frequency distributions,24 supports the notion that the functional properties of the Bw4 motif with respect to KIR3DL1 and NK cell inhibition and/or licensing are the key determinants in protection from disease.
Materials and methods
The study cohort consisted of 907 African American MS cases and 1456 African American controls. All multiple sclerosis subjects met established diagnostic criteria.25, 26 Ascertainment protocols and clinical and demographic characteristics have been summarized elsewhere.16, 18 Principal component analysis and pruned genome-wide autosomal non-major histocompatibility complex (MHC) single nucleotide polymorphisms (SNPs) with minor allele frequency >1% were used to assess ancestry and control for the effects of population stratification.27
KIR genotyping
DNA samples were collected from patients and KIR typing was performed for presence or absence of KIR genes by the LABType SSO KIR typing (OneLambda, Inc., Canoga Park, CA, USA). The typing system can distinguish 8 inhibitory genes (KIR2DL1-2DL5 and KIR3DL1-3DL3), 6 activating genes (KIR2DS1-2DS5 and KIR3DS1) and 2 pseudogenes (KIR2DP1 and KIR3DP1).
HLA genotyping
Genotypes for HLA-DRB1, HLA-A, -B and -C were obtained by sequence specific oligonucleotide probes using the LABType SSO HLA typing (OneLambda, Inc.).
Statistical analysis
All statistical analysis was performed using the R language for statistical computing.28 All single-locus tests for association were performed using standard chi-squared analysis with the ‘chisq.test’ function in the R base package. Odds ratios and confidence intervals were calculated using the ‘epitools’ package for R.29 In the case of low-frequency cells, as is common in HLA data, alleles with expected counts <5 were combined into a single ‘binned’ category prior to analysis.30 Haplotype estimation and association tests were performed using the ‘haplo.stats’ package.31, 32
References
Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M et al. HLA-C–dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012; 367: 805–816.
Parham P, Moffett A . Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 2013; 13: 133–144.
Bashirova AA, Thomas R, Carrington M . HLA/KIR restraint of HIV: surviving the fittest. Annu Rev Immunol 2011; 29: 295–317.
Altfeld M, Fadda L, Frleta D, Bhardwaj N . DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol 2011; 11: 176–186.
Biron CA . Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol 1997; 9: 24–34.
Parham P . Influence of KIR diversity on human immunity. Adv Exp Med Biol 2005; 560: 47–50.
Colonna M, Moretta A, Vely F, Vivier E . A high-resolution view of NK-cell receptors: structure and function. Immunol Today 2000; 21: 428–431.
Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A . Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006; 18: 151–158.
Kaur G, Trowsdale J, Fugger L . Natural killer cells and their receptors in multiple sclerosis. Brain 2013; 136 (Pt 9): 2657–2676.
Jelcic I, Hsu KC, Kakalacheva K, Breiden P, Dupont B, Uhrberg M et al. Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis. Mult Scler 2012; 18: 951–958.
Bettencourt A, Silva AM, Carvalho C, Leal B, Santos E, Costa PP et al. The role of KIR2DS1 in multiple sclerosis—KIR in Portuguese MS patients. J Neuroimmunol 2014; 269: 52–55.
Fusco C, Guerini FR, Nocera G, Ventrella G, Caputo D, Valentino MA et al. KIRs and their HLA ligands in remitting-relapsing multiple sclerosis. J Neuroimmunol 2010; 229: 232–237.
Lorentzen AR, Karlsen TH, Olsson M, Smestad C, Mero IL, Woldseth B et al. Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann Neurol 2009; 65: 658–666.
Wallin MT, Culpepper WJ, Coffman P, Pulaski S, Maloni H, Mahan CM et al. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain 2012; 135 (Pt 6): 1778–1785.
Langer-Gould A, Brara SM, Beaber BE, Zhang JL . Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology 2013; 80: 1734–1739.
Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004; 63: 2039–2045.
Cree BA, Reich DE, Khan O, De Jager PL, Nakashima I, Takahashi T et al. Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Arch Neurol 2009; 66: 226–233.
Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, Khan O et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004; 74: 160–167.
Caillier SJ, Briggs F, Cree BA, Baranzini SE, Fernandez-Vina M, Ramsay PP et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol 2008; 181: 5473–5480.
Hollenbach JA, Nocedal I, Ladner MB, Single RM, Trachtenberg EA . Killer cell immunoglobulin-like receptor (KIR) gene content variation in the HGDP-CEPH populations. Immunogenetics 2012; 64: 719–737.
Hollenbach JA, Oksenberg JR . The immunogenetics of multiple sclerosis: A comprehensive review. J Autoimmun 2015; 64: 13–25.
Pando MJ, Gardiner CM, Gleimer M, McQueen KL, Parham P . The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J Immunol 2003; 171: 6640–6649.
Norman PJ, Hollenbach JA, Nemat-Gorgani N, Guethlein LA, Hilton HG, Pando MJ et al. Co-evolution of Human Leukocyte Antigen (HLA) Class I Ligands with Killer-Cell Immunoglobulin-Like Receptors (KIR) in a Genetically Diverse Population of Sub-Saharan Africans. PLoS Genet 2013; 9: e1003938.
Fernandez Vina MA, Hollenbach JA, Lyke KE, Sztein MB, Maiers M, Klitz W et al. Tracking human migrations by the analysis of the distribution of HLA alleles, lineages and haplotypes in closed and open populations. Philos Trans R Soc Lond B Biol Sci 2012; 367: 820–829.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.
Isobe N, Madireddy L, Khankhanian P, Matsushita T, Caillier SJ, More JM et al. An ImmunoChip study of multiple sclerosis risk in African Americans. Brain 2015; 138 (Pt 6): 1518–1530.
R Development Core Team R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2008.
Aragon T . epitools: Epidemiology Tools. R package version 0.5-7, 2012.
Hollenbach JA, Mack SJ, Thomson G, Gourraud PA . Analytical methods for disease association studies with immunogenetic data. Methods Mol Biol 2012; 882: 245–266.
Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA . Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425–434.
Sinnwell J, Schaid D . haplo.stats: Statistical Analysis of Haplotypes with Traits and Covariates when Linkage Phase is Ambiguous. R package version 1.7.1, 2015.
Acknowledgements
The authors thank the multiple sclerosis patients and healthy controls who participated in this study. We also thank Nezih Cereb and Soo Young Yang at Histogenetics Inc., and Hanne Harbo for useful discussion. This study was supported by grants from the National Institute of Health (R01NS046297 and U19NS095774). Recruitment of study participants and sample acquisition was supported by the National Multiple Sclerosis Society (RG2899-D11).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on Genes and Immunity website
Supplementary information
Rights and permissions
About this article
Cite this article
Hollenbach, J., Pando, M., Caillier, S. et al. The killer immunoglobulin-like receptor KIR3DL1 in combination with HLA-Bw4 is protective against multiple sclerosis in African Americans. Genes Immun 17, 199–202 (2016). https://doi.org/10.1038/gene.2016.5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gene.2016.5
- Springer Nature Limited
This article is cited by
-
Innate receptors modulating adaptive T cell responses: KIR-HLA interactions and T cell-mediated control of chronic viral infections
Immunogenetics (2023)
-
Analysis of whole exome sequencing in severe mental illness hints at selection of brain development and immune related genes
Scientific Reports (2021)
-
Variations in killer-cell immunoglobulin-like receptor and human leukocyte antigen genes and immunity to malaria
Cellular & Molecular Immunology (2020)
-
High resolution HLA analysis reveals independent class I haplotypes and amino-acid motifs protective for multiple sclerosis
Genes & Immunity (2019)